GlassScriptPhysician profile
Gordon Todd Robbins
NPI 1639523608
$13,510.03
in general payments reported to CMS, 2019-2025
31 companies · $8,982 in 2025
The $8,982 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.36 · 2021: $229 · 2022: $753 · 2023: $1,241 · 2024: $2,285 · 2025: $8,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,530 · Honoraria: $4,500 · Travel and Lodging: $742 · Consulting Fee: $600 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,529.71 |
| Honoraria | $4,500.00 |
| Travel and Lodging | $742.21 |
| Consulting Fee | $600.00 |
| Education | $135.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $5,437.78 | 2023-2025 | Sucraid, Sucraid |
| Abbvie INC. | $1,293.65 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Olympus Medical Systems Corporation | $1,000.00 | 2025 | Gastrointestinal Videoscope |
| Boston Scientific Corporation | $823.99 | 2022-2025 | Exalt Model D, General - Polypectomy, Agile Esophageal |
| Janssen Biotech, INC. | $751.25 | 2023-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $623.21 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $501.31 | 2020-2025 | Ocaliva |
| Medtronic, INC. | $488.27 | 2022-2025 | Gi Genius, Nexpowder, Interstim |
| Lilly USA, LLC | $384.04 | 2023-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $226.20 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $196.85 | 2024-2025 | Entyvio |
| Gilead Sciences, INC. | $174.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $149.18 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $134.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $132.37 | 2024-2025 | Zenpep, Vowst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $131.28 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $125.45 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $123.17 | 2023 | Zeposia |
| Merit Medical Systems INC | $115.06 | 2025 | Esophyx |
| Celgene Corporation | $110.86 | 2023-2024 | Zeposia |
| Pfizer INC. | $93.15 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $80.06 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $68.51 | 2024-2025 | Iqirvo |
| Enterra Medical, INC. | $65.01 | 2025 | |
| Ironwood Pharmaceuticals, INC | $61.74 | 2024 | |
| Novo Nordisk INC | $51.99 | 2025 | Wegovy |
| Celltrion USA INC. | $51.59 | 2023-2024 | Zymfentra, Yuflyma |
| Axonics, INC. | $45.76 | 2024 | Axonics, Bulkamid |
| Alnylam Pharmaceuticals INC. | $27.34 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.69 | 2023 | |
| Merck Sharp & Dohme LLC | $18.33 | 2023 | Zinplava, Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.